Vertiv is projecting another year of sales growth as the bustling data center market continues to provide it with strong pipeline activity.

Q4 2024 Management View CEO Ted Klinck highlighted significant growth potential over the next few years, driven by three main factors: lease-up of core properties, stabilization of the development ...

We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

Assemblymember Bennett’s AB 506 voids contracts between California consumers and online pet brokers that require a ...

China’s top oil and gas companies are selling off underperforming assets and streamlining operations as part of ongoing ...